Welcome to our dedicated page for Tyra Biosciences news (Ticker: TYRA), a resource for investors and traders seeking the latest updates and insights on Tyra Biosciences stock.
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company based in Carlsbad, CA, focused on developing next-generation precision medicines that target significant opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The Company leverages its proprietary precision medicine platform, SNÅP, to enable rapid and precise drug design through iterative molecular SNÅPshots that predict genetic alterations likely to cause acquired resistance to existing therapies.
Tyra’s lead product candidate, TYRA-300, is an investigational oral FGFR3-selective inhibitor aimed at treating cancer and skeletal dysplasias, including achondroplasia. TYRA-300 is currently being evaluated in a multi-center, open-label Phase 1/2 clinical study, SURF301 (Study in Untreated and Resistant FGFR3+ Advanced Solid Tumors). SURF301 is designed to determine the optimal and maximal tolerated doses (MTD) and the recommended Phase 2 dose (RP2D) of TYRA-300, as well as to evaluate its preliminary antitumor activity. TYRA-300 has demonstrated positive preclinical results in skeletal dysplasias, and Tyra expects to submit an Investigational New Drug (IND) application to the FDA for a Phase 2 clinical study in pediatric achondroplasia in 2024.
Another key product in development is TYRA-200, an investigational oral FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations and resistance mutations for the treatment of cancer. TYRA-200 is currently undergoing evaluation in a multi-center, open-label Phase 1 clinical study, SURF201 (Study in Previously treated and Resistant FGFR2+ Cholangiocarcinoma and Other Advanced Solid Tumors). SURF201 is designed to determine the optimal and MTD and RP2D of TYRA-200 and to evaluate its preliminary antitumor activity.
Tyra has recently achieved significant milestones, including the FDA granting Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation to TYRA-300 for treating achondroplasia. The Company is also actively presenting research findings at major scientific congresses such as the American Society for Bone and Mineral Research (ASBMR) and the American Society of Human Genetics (ASHG).
In 2024, Tyra secured approximately $200 million in funding via a securities purchase agreement with institutional and accredited investors, led by RA Capital Management. This financial boost strengthens Tyra's balance sheet as the company advances its clinical development programs and leverages the SNÅP platform for discovering new drug candidates.
Tyra Biosciences' vision is to provide novel therapeutic options for patients with unmet medical needs by developing best-in-class precision medicines. Their ongoing research, clinical trials, and financial stability position them well to achieve this goal.
Tyra Biosciences (Nasdaq: TYRA) announced the expansion of TYRA-300's development into achondroplasia following promising preclinical results. The oral FGFR3 selective inhibitor exhibited significant growth and bone length increases in preclinical models, including a 17.6% increase in body length and notable femur and tibia length improvements. A Phase 2 clinical study is planned for 2024, addressing unmet medical needs in children with achondroplasia. Additionally, TYRA has received FDA clearance for a Phase 1 study of TYRA-200, aimed at advancing its pipeline. A conference call was held on March 1 to discuss these developments.
Tyra Biosciences (Nasdaq: TYRA), a precision oncology company, announced its participation in two upcoming investor conferences. CEO Todd Harris will engage in a fireside chat at the Cowen 43rd Annual Healthcare Conference on March 7, 2023, at 10:30 am ET. Additionally, he will provide a company overview virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 12:00 pm ET. Live and archived webcasts can be accessed through the Investor section of the TYRA website. Tyra focuses on developing therapies to combat tumor resistance, utilizing its proprietary SNÅP platform to design selective inhibitors targeting FGFR.
Tyra Biosciences has initiated the SURF301 Phase 1/2 clinical study for TYRA-300, an oral FGFR3-selective inhibitor for metastatic urothelial carcinoma, marking a pivotal shift to a clinical-stage company. The first patient has been dosed, with an emphasis on addressing unmet needs in both FGFR resistant and naïve populations. The study aims to establish optimal dosing and evaluate preliminary antitumor activity. Results and updates will be shared as data matures, with further details available on their website.
Tyra Biosciences (Nasdaq: TYRA) announced its participation in key investor conferences on November 14 and 15-17, 2022. CEO Todd Harris will engage in fireside chats at both events, aiming to showcase the company's innovations in precision oncology. The H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference will feature a chat available on demand, while the Jefferies London Healthcare Conference will include a live chat on November 15 at 10:50 am ET. Webcasts of these discussions will be accessible on the TYRA Investor section.
Tyra Biosciences, Inc. (TYRA) reported its third-quarter 2022 financial results, highlighting a net loss of $12.5 million, an increase from $6.6 million in Q3 2021. Research and development expenses rose to $10.9 million, compared to $5.5 million in the prior year. As of September 30, 2022, cash and cash equivalents stood at $263.2 million. The company is focused on advancing its pipeline, which includes the initiation of the SURF301 study for TYRA-300 and filing an IND for TYRA-200 by year-end 2022.
Tyra Biosciences (Nasdaq: TYRA) announced a leadership transition, with Esther van den Boom stepping down as Chief Financial Officer to become an advisor at the end of 2022. Alan Fuhrman will assume the CFO role on January 1, 2023. CEO Todd Harris praised van den Boom's contributions and expressed confidence in Fuhrman's experience guiding companies through growth phases, including clinical development. Fuhrman looks forward to advancing TYRA's precision oncology pipeline, particularly the FGFR-targeting therapies, including TYRA-300, which has received FDA IND clearance.
Tyra Biosciences (Nasdaq: TYRA) will present preclinical data on its FGFR1/2/3 inhibitor, TYRA-200, at the 34th EORTC-NCI-AACR Symposium in Barcelona, Spain, from October 26-28, 2022. The presentation is scheduled for October 26 and focuses on TYRA-200's effectiveness against FGFR2 fusions, molecular brake mutations, and gatekeeper resistance, with the aim of enhancing outcomes for cancer patients. This event is pivotal as the company seeks to advance its pipeline targeting critical genetic alterations affecting cancer treatment.
Tyra Biosciences (Nasdaq: TYRA), a precision oncology firm, announced its participation in key investor conferences. Management will present a pre-recorded session at H.C. Wainwright's 24th Annual Global Investment Conference from September 12-14, 2022, with the presentation available on September 12 at 7 AM ET. Additionally, Tyra will be featured at the Cantor Oncology, Hematology & HemeOnc Conference on September 28, 2022, with a panel discussion at 11:30 AM ET. Tyra is focused on therapies to overcome tumor resistance and is developing selective FGFR inhibitors.
Tyra Biosciences, Inc. (Nasdaq: TYRA) announced the presentation of preclinical data on TYRA-300, an FGFR3-selective inhibitor, at the ESMO 2022 Congress in Paris from September 9-13, 2022. CEO Todd Harris highlighted the promising anti-tumor activity of TYRA-300 compared to other agents. This data supports the upcoming SURF301 Phase 1/2 clinical study, which the FDA has already authorized. The poster presentation will occur on September 12, 2022, showcasing the drug's potential in treating metastatic urothelial carcinoma.
Tyra Biosciences announced the FDA's IND clearance for its SURF301 study of TYRA-300, an FGFR3-selective inhibitor for bladder cancer. The company is on track to file an IND for TYRA-200 in the second half of 2022 and reported a strong cash position of $275.1 million as of June 30, 2022. Despite progress, the net loss for Q2 2022 was $15.1 million, up from $5.5 million in Q2 2021, with increased R&D expenses of $12.0 million compared to $4.4 million from the prior year.
FAQ
What is the current stock price of Tyra Biosciences (TYRA)?
What is the market cap of Tyra Biosciences (TYRA)?
What is Tyra Biosciences' core focus?
What is TYRA-300?
What is the SNÅP platform?
What are the current clinical trials for TYRA-300?
What designations has TYRA-300 received?
What is TYRA-200?
What recent funding did Tyra Biosciences secure?
Who are the key people in Tyra Biosciences?
Where is Tyra Biosciences located?
How can I learn more about Tyra Biosciences?
